좌골신경통 치료 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of sciatica treatment Market

The global sciatica treatment market was valued at USD 5.92 billion in 2025 and is projected to grow from USD 6.52 billion in 2026 to USD 14.42 billion by 2034, registering a strong CAGR of 10.44% during the forecast period. North America dominated the market with a 46.1% share in 2025, supported by high awareness of chronic lower back pain, increased prescription volumes, and the presence of leading pharmaceutical companies.

Sciatica, also known as lumbar radicular pain, is characterized by pain radiating from the lower back to the legs due to compression or irritation of the sciatic nerve. The rising incidence of herniated discs, spinal stenosis, and lumbar radiculopathy is driving demand for effective pharmacological and interventional treatment options worldwide.

Market Drivers

A key driver of market growth is the increasing prevalence of sciatica globally, with annual incidence rates ranging from 1.0% to 5.0% and lifetime prevalence between 13% and 40%. The growing use of over-the-counter and prescription drugs, including NSAIDs, corticosteroids, antidepressants, and opioids, has significantly contributed to treatment adoption.

Rising awareness of advanced treatment modalities such as epidural steroid injections and analgesic therapies, along with increased clinical trial activity by market players, is further accelerating market expansion. Additionally, the lack of long-term FDA-approved therapies has encouraged companies to invest in innovative drug development programs.

COVID-19 Impact

The COVID-19 pandemic negatively affected the sciatica treatment market in 2020 due to reduced hospital visits and disruptions in pharmaceutical manufacturing and supply chains. Prescription volumes declined as healthcare systems prioritized COVID-19 care.

However, post-pandemic recovery led to a rebound in patient visits for chronic conditions. By 2021, the relaxation of restrictions resulted in increased demand for sciatica treatments, with pharmaceutical companies witnessing growth in prescription drug sales across hospitals and retail pharmacies.

Market Trends

One of the major trends shaping the market is the rise in awareness programs initiated by healthcare authorities and research institutions. Increased public knowledge about sciatica symptoms, risk factors, and treatment options has improved early diagnosis and treatment uptake.

National and regional initiatives focusing on chronic lower back pain management and the promotion of non-opioid pain therapies are influencing prescribing patterns. The growing availability of minimally invasive procedures and non-opioid medications across healthcare settings is further strengthening market growth.

Restraining Factors

Despite strong growth prospects, the market faces restraints due to side effects and complications associated with long-term sciatica treatments. Chronic use of corticosteroids, opioids, and invasive procedures can lead to significant morbidity, limiting their adoption.

Additionally, sciatica treatment imposes a substantial economic burden due to high direct and indirect healthcare costs. Limited long-term efficacy of existing therapies and concerns regarding complications such as infections and systemic side effects may restrict market growth.

Segmentation Analysis

By Type:

The chronic sciatica segment dominated the market with a 71.47% share in 2026, driven by the high prevalence of long-lasting pain and increased use of epidural injections and opioid therapies. The acute segment is expected to grow steadily due to rising awareness and early treatment adoption.

By Drug Class:

The NSAIDs segment accounted for 44.17% of the market in 2026, supported by widespread availability, affordability, and frequent prescriptions. Corticosteroids are anticipated to witness the fastest growth due to rising demand for epidural steroid injections.

By Distribution Channel:

The retail and online pharmacies segment dominated with an 80.52% share in 2026, driven by high out-of-pocket spending and easy access to pain management medications. Hospital pharmacies are expected to grow steadily due to increasing patient admissions.

Regional Insights

• North America: Valued at USD 2.73 billion in 2025, driven by high prescription rates and awareness. The U.S. market is projected to reach USD 2.93 billion by 2026.
• Europe: Moderate growth supported by high disease prevalence and structured pain management guidelines.
• Asia Pacific: Strong growth potential due to rising lower back pain incidence and government initiatives. By 2026, Japan is projected to reach USD 0.28 billion, China USD 0.24 billion, and India USD 0.17 billion.
• Latin America & Middle East & Africa: Expected to grow steadily due to expanding access to pain management therapies.

Competitive Landscape

Key players include Pfizer Inc., Abbott, Bayer AG, Johnson & Johnson, Novartis AG, GSK plc., and Sorrento Therapeutics. These companies focus on portfolio expansion, clinical trials, and strategic collaborations to strengthen their market presence.

Conclusion

The global sciatica treatment market is set to witness robust growth from 2025 to 2034, driven by rising disease prevalence, increasing awareness, and growing demand for effective pain management solutions. While concerns regarding side effects and long-term efficacy remain, ongoing clinical research, new drug development, and supportive healthcare initiatives are expected to sustain market momentum. By 2034, the market is projected to reach USD 14.42 billion, reflecting the expanding need for advanced and safer sciatica treatment options worldwide.

Segmentation By Type

• Acute
• Chronic

By Drug Class

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• Antidepressants
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail & Online Pharmacies

By Region

• North America (By Type, Drug Class, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Sciatica, By Key Countries, 2025
• 4.2. Recent Product Launches, By Key Players
• 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.4. Impact of COVID-19 on the Global Market

5. Global Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Acute
  • 5.1.2. Chronic
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 5.2.2. Corticosteroids
  • 5.2.3. Antidepressants
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail & Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East and Africa

6. North America Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Acute
  • 6.1.2. Chronic
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.2.2. Corticosteroids
  • 6.2.3. Antidepressants
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail & Online Pharmacies
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Acute
  • 7.1.2. Chronic
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 7.2.2. Corticosteroids
  • 7.2.3. Antidepressants
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail & Online Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Rest of Europe

8. Asia Pacific Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Acute
  • 8.1.2. Chronic
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 8.2.2. Corticosteroids
  • 8.2.3. Antidepressants
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail & Online Pharmacies
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Acute
  • 9.1.2. Chronic
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 9.2.2. Corticosteroids
  • 9.2.3. Antidepressants
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail & Online Pharmacies
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Acute
  • 10.1.2. Chronic
• 10.2. Market Analysis, Insights and Forecast - By Drug Class
  • 10.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 10.2.2. Corticosteroids
  • 10.2.3. Antidepressants
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail & Online Pharmacies
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of MEA

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Pfizer Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. Abbott
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Bayer AG
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Endo International plc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Johnson & Johnson Services, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. GSK plc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. Novartis AG
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Bristol Myers Squibb
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. Amneal Pharmaceuticals LLC.
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. financials (Based on Availability)
  • 11.2.10. Sorrento Therapeutics
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. financials (Based on Availability)